Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986218 +/- Nivolumab in Advanced Solid Tumors
NCT03110107Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of BMS-986218 in solid tumor (advanced stage), melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started May 2017; status: terminated.
02
Drugs
BMS-986218
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03110107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110107.